[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20050281A2 - Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes - Google Patents

Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Info

Publication number
HRP20050281A2
HRP20050281A2 HR20050281A HRP20050281A HRP20050281A2 HR P20050281 A2 HRP20050281 A2 HR P20050281A2 HR 20050281 A HR20050281 A HR 20050281A HR P20050281 A HRP20050281 A HR P20050281A HR P20050281 A2 HRP20050281 A2 HR P20050281A2
Authority
HR
Croatia
Prior art keywords
pyridylmethyl
medicament
manufacture
myelodysplastic syndromes
treatment
Prior art date
Application number
HR20050281A
Other languages
English (en)
Croatian (hr)
Inventor
Han Dugan Margaret
List Alan
Original Assignee
Novartis Ag
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, The Arizona Board Of Regents On Behalf Of The University Of Arizona filed Critical Novartis Ag
Publication of HRP20050281A2 publication Critical patent/HRP20050281A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050281A 2002-09-24 2005-03-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes HRP20050281A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (1)

Publication Number Publication Date
HRP20050281A2 true HRP20050281A2 (en) 2006-07-31

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050281A HRP20050281A2 (en) 2002-09-24 2005-03-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Country Status (22)

Country Link
US (1) US20060128716A1 (xx)
EP (1) EP1545534B1 (xx)
JP (1) JP2006502195A (xx)
KR (1) KR20050074450A (xx)
CN (1) CN100372535C (xx)
AT (1) ATE359789T1 (xx)
AU (1) AU2003299065B2 (xx)
BR (1) BR0314647A (xx)
CA (1) CA2499738A1 (xx)
CR (1) CR7754A (xx)
DE (1) DE60313344T2 (xx)
EC (1) ECSP055700A (xx)
ES (1) ES2285251T3 (xx)
HR (1) HRP20050281A2 (xx)
MX (1) MXPA05003161A (xx)
NO (1) NO20051936L (xx)
PL (1) PL374696A1 (xx)
PT (1) PT1545534E (xx)
RS (1) RS20050228A (xx)
RU (1) RU2353364C2 (xx)
WO (1) WO2004028542A1 (xx)
ZA (1) ZA200502212B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP4673977B2 (ja) * 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
ES2438535T3 (es) * 1999-12-06 2014-01-17 Geistlich Pharma Ag Taurolidina o taurultamo para uso en el tratamiento de tumores de próstata, de colon, de pulmón y para el tratamiento del glioblastoma multiforme recurrente

Also Published As

Publication number Publication date
RU2353364C2 (ru) 2009-04-27
NO20051936L (no) 2005-06-23
RS20050228A (xx) 2007-08-03
EP1545534B1 (en) 2007-04-18
WO2004028542A1 (en) 2004-04-08
MXPA05003161A (es) 2005-09-12
PL374696A1 (en) 2005-10-31
CN1684684A (zh) 2005-10-19
ATE359789T1 (de) 2007-05-15
BR0314647A (pt) 2005-08-02
RU2005112711A (ru) 2006-02-27
US20060128716A1 (en) 2006-06-15
KR20050074450A (ko) 2005-07-18
PT1545534E (pt) 2007-06-22
DE60313344D1 (de) 2007-05-31
CA2499738A1 (en) 2004-04-08
EP1545534A1 (en) 2005-06-29
ZA200502212B (en) 2006-02-22
DE60313344T2 (de) 2008-01-03
CR7754A (es) 2005-12-02
ES2285251T3 (es) 2007-11-16
ECSP055700A (es) 2005-08-11
JP2006502195A (ja) 2006-01-19
AU2003299065A1 (en) 2004-04-19
AU2003299065B2 (en) 2006-10-26
CN100372535C (zh) 2008-03-05

Similar Documents

Publication Publication Date Title
DE60329001D1 (en) 8-hydroxychinolinderivate
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
MY119375A (en) Treatment of tinnitus using neuroprotective agents
SE0400184D0 (sv) New therapeutical use
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
GB0130677D0 (en) Medicaments and novel compounds
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
EP1178796A4 (en) AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
HK1061817A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
HRP20050281A2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
SE0004827D0 (sv) Therapeutic compounds
ZA200209714B (en) Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV.
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060808

Year of fee payment: 4

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn